Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Presentation - Madrigal Pharmaceuticals will present at the 43rd Annual J P Morgan Healthcare Conference on January 15 2025 at 2 15 pm PT [1] - The presentation will be webcast live and accessible via Madrigalâs Investor Relations Site Events and Presentations [1] Company Overview - Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) a liver disease with significant unmet medical needs [2] - The companyâs lead medication Rezdiffra (resmetirom) is a once-daily oral liver-directed THR-β agonist designed to target key underlying causes of MASH [2] Contact Information - Investor inquiries can be directed to Tina Ventura at IR@madrigalpharma com [3] - Media inquiries can be directed to Christopher Frates at media@madrigalpharma com [3]